AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
AstraZeneca announced plans to limit out-of-pocket expenses for its inhaled respiratory products to $35 per month in the US, mirroring a similar initiative by competitor Boehringer Ingelheim, according to Reuters. Amid growing political scrutiny over high drug prices, senators like Bernie Sanders have criticized leading inhaler manufacturers, prompting investigations into pricing disparities between the US and other countries. AstraZeneca's decision applies to its entire portfolio of respiratory products for patients who are underinsured or have no health coverage.
The rollout of Opill, the first over-the-counter birth control pill approved in the US, began Monday through online sales, according to CNN. Priced at $19.99 for a 1-month supply, Opill’s manufacturer Perrigo say that it offers accessibility and affordability, with discreet packaging to prioritize consumer privacy. This availability is particularly beneficial for individuals in remote areas or facing barriers to accessing traditional health care services, providing greater control over reproductive health choices. Reproductive health experts hope that the online availability marks a significant step in expanding contraceptive access and empowering individuals to make informed decisions about their health.
The expansion of remote patient monitoring services, accelerated by the COVID-19 pandemic, has led to significant growth in Medicare billing for these services, raising concerns about oversight and evidence of their effectiveness, according to Kaiser Health News. While remote monitoring offers potential benefits in managing chronic illnesses and freeing up appointment time, experts warn of a lack of robust evidence and regulatory oversight. As Medicare payments for remote monitoring soar, questions linger about appropriate utilization, patient access, and safeguarding against fraud. CMS says the agency is balancing patient access to the new technology with the need to right fraud and ensure proper reimbursement.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen